jesper-hoiland

Jesper Hoiland becomes president of Novo Nordisk US

pharmafile | August 22, 2013 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |  Novo Nordisk 

Jesper Hoiland has become the new president of diabetes specialist Novo Nordisk in the US.

Hoiland was previously Novo Nordisk’s head of international operations, where he oversaw all of the company’s operations outside of Europe, China, Japan, Korea and North America.

He replaces Jerzy Gruhn, who, having served in the role since 2008, has been appointed to lead the company’s European business.

Advertisement

The changes in leadership have been triggered by the retirement of some of the company’s most experienced leaders, including Martin Soeters, former head of the Europe region.

Successors were identified through Novo Nordisk’s succession management process, part of the company’s annual organisation review.

 

Related Content

hsm_mobile_clinical_trial_istock-872676342

FDA approves Wegovy for treatment of MASH in adults with liver fibrosis

The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …

BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation

BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of …

obesity

Pila Pharma raises SEK 20m to advance new oral obesity treatment

Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital …

The Gateway to Local Adoption Series

Latest content